Summary In this paper, the incidence rates and cumulative incidence of nerve function impairment (NFl) and leprosy reactions over 24 months follow-up of the prospective cohort of 2664 new leprosy cases are presented. Graphs showing the cumulative incidence of NFl relative to time since registration are presented. Hazard ratios (HRs) for the development of NFl for four variables are given. The majority of patients who developed NFl after registration did so in the first year (67% of multibacillary (MB) patients, and 91 % of paucibacillary (PB) patients who developed NFl). Thirty-three percent of all MB patients who developed NFl after registration did so in the second year of fo llow-up. No PB patients developed NFl for the first time in the last 6 months of follow-up. However, seven NFl events occurred amongst PB patients in that period, amongst those who had already had one NFl event. The incidence rate (IR) of NFl amongst MB patients was 24/ 100 person-years at risk (PY AR), and amongst PB patients was 1.3/100 PY AR. The HR for the development of NFl amongst MB patients compared with PB patients was 16 using univariate analysis. Amongst patients who had long-standing NFl present at registration, the IR was 27/100 PY AR compared with l.7/100 PY AR amongst those who did not have long-standing NFl. The HR for developing acute NFl amongst those with long standing NFl present at registration compared with those without was 14 using univariate analysis. When multivariate regression analysis is applied, the apparently significant univariate HRs for sex and age disappeared. The resultant multivariate HR for leprosy group is 8.8, and 6. 1 for the presence/absence of long-standing NFl at registration. In all, 142/ 166 (86%) of all new NFl events were silent, underlining the need for regular nerve fu nction testing. IRs are presented for the four 6-month periods of the 24-month follow-up. They show a clear stepwise reduction over the total period. The IRs amongst MB patients and those with long-standing NFl present at
Introduction
The Bangladesh Acute Nerve Damage Studyregistration are very high at 34 and 41/100 PYAR, respectively, for the first 6 months of fo llow-up. Even during the final 6-month period, the IR is maintained at a moderately high level (18 and 15/100 PY AR, respectively).
Nerve function impairment (NFl) in leprosy is the key outcome of the pathological processes involved in infection by My cobacterium Zeprae. In order to understand more clearly the epidemiology of NFl and its incidence, risk factors and response to treatment, a prospective cohort study has been initiated at the Danish Bangladesh Leprosy Mission (DBLM), and its design, methodology and intake status have been described in an earlier paper. 1
NFl results from a variety of pathological and immunological processes taking place in peripheral nerves. These include the presence of M. Zeprae in the nerve, trauma, oedema causing increased intraneural pressure, vascular changes and hypersensitivity granuloma. 2 Reactive states, including type 1 and type 2 reactions, are widely accepted as common causes of NFl and of these, type 1 or reversal reaction is regarded as the leading cause ? However, nerves are often functionally impaired without developing obvious symptoms such as skin reactions or nerve pain, and this condition is variously called 'silent neuritis', 4 'silent neuropathy , 5 or 'quiet nerve paralysis , . 6 Van Brakel has suggested that epidemiologically silent neuropathy is not equivalent to a 'reversal reaction expressing itself in the nerves', but has multiple aetiologies. 5 In this paper, the incidence rates (IRs) and cumulative incidence of NFl and other reactive phenomena amongst patients in the BANDS cohort are presented for different risk variables (or categories of risk factor) including leprosy group (PBIMB), sex, age and presence or absence of long-standing NFl at registration. Cox's proportional hazards regression analysis has been carried out to determine the HRs of the four variables using both univariate and multivariate methods.
Follow-up of patients included in the cohort is continuing for up to 3 years from the time of registration in the case of paucibacillary (PB) patients, and for up to 5 years for multibacillary (MB) patients. This analysis presents the results at 24 months of follow-up.
Materials and methods

THE PATIENT COHORT AND FOLLOW-UP
The study group is the cohort for the Bangladesh Acute Nerve Damage Study (BANDS). I The 2664 patients recruited over a 12-month period comprise 1481 males (56%) and 1183 females (44%). In all, 2220 (83%) of the patients were PB , and 444 (17%) were MB. Amongst the PB group, 14 patients were reclassified as MB during the course of follow-up, and they were started on MBIMDT. In these patients, a reversal reaction caused skin patches that had been invisible at the time of registration to become visible, thus making reclassifica tion of these patients into the MB group necessary, since classification was based on a count of patches combined with the number of palpable enlarged nerves and skin smear results (> 10 skin patches and enlarged nerves and/or skin smear positive = MB). However, since these cases were correctly diagnosed as PB according to the diagnostic tools available at the time of registration, they have been considered as PB for the purposes of analysis. In other words, the initial classification of PB or MB was 'fixed' for subsequent analysis.
Details of follow-up procedures have been described. l Patients have completed at least 24 months of follow-up after registration, and all analysis in this paper is based on that 24-month period.
Analysis will focus on the incidence of new nerve function impairment (NFl) during follow-up as the main outcome. The definition of NFl used is as follows:
Sensory NFl: reduction by ;::: :: 2 points in the sensory distribution of any one nerve, as tested by ballpoint pen using the standard test sites described. 1 The following nerves were tested for sensory fu nction: ulnar, median and posterior tibial.
Motor NFl: reduction by ;::: :: 2 in the MRC grade of the movement tested of any one nerve as described earlier. The following nerves were tested for motor function: facial, ulnar, median, radial and lateral popliteal.
Full details of testing and other outcome definitions such as type 1 reaction are described in the earlier paper. 1 The testing methods have been validated in a separate publication. 7 In this paper, a patient is said to have developed an 'NFl event' (positive outcome) if he or she has had either sensory or motor NFl, or both, unless stated otherwise.
STATISTICAL METHODS
IRs have been calculated using the number of patients developing NFl or reactions as the numerator, and cumulative person-years at risk as the denominator, expressed as 100 person years at risk (PYAR).
Patients who were lost to follow-up, died or who were transferred out of the project were included in the denominator for as long as follow-up was possible, up to 24 months from the time of registration. Patients were censored from the denominator as soon as they developed an event of the type for which the IR was being calculated (i.e. NFl or reaction).
Graphs showing the cumulative incidence of NFl against time since registration amongst the cohort patients are shown. These curves show the probability of developing NFl at any given time, and are the inverse of survival curves. The log rank test has been carried out to assess the significance of differences between the curves at the mid-points in follow-up, i.e. 12 months, and the P-value has been given on the graphs. The cumulative incidence at 24 months is also given numerically in the tables.
Cox's proportional hazards regression analysis (using a backward stepwise method) has been carried out to determine the hazards ratio for the four variables. 8 Univariate analysis shows the HR for each variable considered separately, and multivariate analysis has been used to build a model fitted to the data in order to determine the prognostic strength of each variable for the development of NFL The univariate HR is more accurate than a simple relative risk calculated using a 2 x 2 table, since it makes allowance for censoring of patients from the calculation once they develop an event. However, the HR may be interpreted in the same way as relative risk.
NUMBER OF AT-RISK CASES USED IN CALCULATIONS
The number of at-risk cases (which appears in the denominator of the incidence calculation, to determine the number of person-years at risk) is the total number of patients in the BANDS cohort (2664), less the number of patients who had an episode of NFl or reaction that needed prednisolone treatment at registration (119), less the number of other patients who received prednisolone treatment at the time of registration for any other reason (e.g. those who did not strictly fulfil the standard treatment criteria, but who still received prednisolone) (35), leaving the total number of patients entering the denominator at the beginning of the study as 25 10.
RISK FACTORS CONSIDERED FOR ANALYSIS
Four variables have been selected for analysis. They are: sex, leprosy group (MBIPB), age (adult/child) and the presence or absence of long-standing Nfl at registration (i.e. >6 months duration). These four have been selected because they are fundamental to the assessment of a leprosy patient at registration, and can be carried out without difficulty in any control programme. Classification into MB and PB for treatment purposes is usually carried out using either the WHO method of counting skin patches 9 or a similar procedure such as the Bangladesh system of counting patches and enlarged nerves, lO in combination with skin smear results.
As already mentioned, all patients with acute NFl/reaction (::;6 months duration) needing treatment at registration have been excluded from analysis, since it is difficult to be certain of whether a subsequent 'NFl event' truly represents a new episode or a continuation of the first. In addition, this group of patients' outcome will have been modulated by having received prednisolone therapy, and therefore a comparison with patients who did not receive prednisolone is not possible. However, it was felt important to consider whether patients who had long-standing NFl at registration (>6 months duration) are or are not at increased risk of developing another episode.
The reliability of long-standing Nfl present or absent at registration as a predictive variable for Nfl outcome was tested by carrying out a Cox's multivariate regression analysis using sex, leprosy group and age as dependent variables, to see whether there was a significant difference between the two groups with long-standing Nfl present or absent.
Proportions and rates have been expressed using two-digit precision. Table 1 shows the status of the BANDS cohort patients at 24 months from the time of registration. Patients were considered to be lost to follow-up if their date of expected contact with DBLM staff was more than 3 months overdue despite active attempts at tracing. Out of 2220 PB patients, 14 were reclassified as MB during treatment, leaving 2206. Of these, 2127 completed PBIMDT within 9 months, a treatment completion rate of 96%. It is not possible to calculate treatment completion rates for the MB group since 36 months has not yet elapsed for all MB patients. Relapse rates have not been presented since 2 years of follow up is not long enough to assess this in the standard way.
Results
STATUS OF THE COHORT AT 24 MONTHS, AND TREATMENT COMPLETION RATE
PROPORTION OF PATIENTS DEVELOPING ACUTE NFl FOR THE FIRST TIME DURING FOLLOW-UP, AND TOTAL NUMBER OF NFl EVENTS OCCURRING IN THE COHORT.
Figure 1 shows the number of patients who had developed Nfl by the time of registration and during 24 months of follow-up, divided into 6-month periods, and broken down by leprosy group. Ten percent (7.6-14) of all MB patients had Nfl present at the time of registration, and a further 25% (21-30) went on to develop NFl during the first 24 months of follow-up (rounding up the hidden decimal places), which is a total prevalence of acute NFl of 36% (3 1 -40) amongst MB cases from registration to the end of 24 months follow-up. Amongst PB cases, 2.0% (1.5-2.7) had acute NFl present at registration, and a further 2.4% (1.8-3.2) went on to develop an episode of NFl during follow-up, which is a total of 4.4% (3.6-5.4). In 35% (29-41) of all patients with acute NFl, the event took place before registration. Conversely, In all, 9.6% (5.8-15) of all patients who developed Nfl during follow-up did so in the final 6 months, all of them MB patients. Although most MB patients who developed Nfl during treatment did so in the first year after registration, a third did so in the second year [33%, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) ]. For the PB group, 9.3% (3.5-21) of those who developed NFl during follow-up did so in the second year, all of those in the first 6 months of that year. Of the total cohort, 8.3% (6.0-11) of the MB patients developed new NFl in the second year of treatment, compared with 0.2% (0. 1 -0.6) of the PB patients. Figure 2 shows the total number of NFl events (Figure 1 shows patient numbers developing NFl) occurring during the 24-month follow-up period, again presented in 6-month blocks with breakdown by leprosy group. The pattern is quite different from that of Figure 1 , and is due to the number of patients who developed repeated NFl events. Whilst Figure 1 shows that the number of patients developing Nfl for the first time diminishes over 2 years, the total number of NFl events does not diminish to the same extent, the numbers being sustained by a core of patients who suffered repeated events of NFL Indeed, the number of NFl events amongst MB patients is nearly constant over the 2 years. The number of events amongst PB patients is smaller, but seven events [8%, (3.6-1 7)] occurred in the last 6 months, during a time when no new patients developed a new NFl event. 
RELIABILITY OF LONG· STANDING NFl AS A PREDICTIVE VARIABLE
A Cox multivariate analysis showed no significant difference between the two groups of patients defined by the presence or absence of long-standing NFl at registration. P-values for interaction were 0. 14 for sex, 0. 18 for leprosy group and 0.63 for age. It was concluded that the presence/absence of long-standing NFl at registration is acceptable to use in analysis.
INCIDENCE RATES AND CUMULATIVE INCIDENCE OF NERVE FUNCTION IMPAIRMENT, TYPE 1
REACTION AND SILENT NFl DURING FOLLOW-UP Table 2 shows the IRs expressed per 100 person-years at risk (PY AR) of NFl, and the cumulative incidence at 24 months. Results are shown for all episodes of NFl (including 'silent' NFl, and NFl occurring as part of a type 1 or type 2 reaction), and for sensory and motor NFl separately. The definition of NFl used strictly follows the definitions given in the 
.71100 PYAR cf. 1.3/100 PYAR) in the cohort. The IR of SNFI amongst patients with long-standing NFl is proportionately higher compared with that for MNFI , the rate being triple rather than double (22/100 PYAR for SNFI, cf. 7.5/100 PYAR for MNFI). Table 3 shows the same statistics for type 1 reaction. type 1 reaction as defined for Table 3 means patients with a skin reaction with or without NFL The overall IR for type 1 reactions is nearly a third of the rate for NFl, 1.4/100 PY AR compared with 3.711 00 PY AR. There is an interesting contrast in IRs between the type 1 reaction patients and the NFl patients. There is a IS-fold difference between the IRs for development of NFl amongst the patients in the presence/absence of NFl at registration category (27 versus 1.70); but only a 2-fold difference in the same category for the development of type 1 reaction (3.1 versus 1.2). Table 4 shows IRs and cumulative incidences for patients with silent NFl (silent neuropathy). The pattern for silent NFl is very similar to that for NFl in general, which is not surprising since the majority of NFl cases were in fact silent (142/166, 86%). The IR for silent NFl is 3.2/100 PYAR.
Only eight patients developed a type 2 reaction during follow-up, an IR of 1.6 events per 100 PY AR amongst the MB leprosy group.
GRAPHS SHOWING CUMULATIVE INCIDENCE OF DEVELOPING NFl
Figures 3, 4, 5 and 6 show the cumulative incidence of NFl over the 24 months of follow-up. The four graphs show curves for the respective variables of sex, leprosy group, age, and presence or absence of long-standing NFl at registration (i.e. >6 months duration). All four curves show significant differences between the four pairs of risk factors, which are most marked for leprosy group and the presence/absence of long-standing NFl at registration. The log rank test shows the difference between survival probabilities at 12 months to be statistically significant with a P-value of <0.00 1 for all four curves (X 2 with 1 df for male/ female = 14; for MBIPB = 265; for adult/child = 14; for long-standing NFl present/absent at registration = 326). Table 5 shows the IRs for development of the first event of NFl, expressed for the four 6-month periods comprising the 24 months of follow-up. The number of events occurring during these 6-month periods have been summed to produce the numerator, and the number of days at risk during that period only used for the denominator. These IRs have been calculated for the four different risk variables of sex, leprosy group, age, and presence or absence of long-standing Nfl at registration. For each variable there is a stepwise reduction in IR for successive 6-month periods. The IR amongst MB patients during the first 6 months 
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Long term NFl present Months of follow-up after registration is very high at 34/100 PYAR, and this has only halved to 18/100 by the last 6 months of follow-up. However, for the PB group the low IR of 3.3/100 PY AR has reduced to zero by the last 6 months of follow-up. Amongst patients with and without long-standing NFl at registration, a similar but even more marked pattern exists. Here, the IR amongst patients with long-standing NFl present is 411100 PYAR, reducing by a factor of nearly 3-15/100 PY AR in the last 6 months of follow-up. Amongst patients with no long-standing NFl present at registration, the IR in the first 6 months is 3.7/100 PY AR, reducing by a factor of over 7-0.5/100 PY AR by the end of fo llow-up. The IR in the first 6 months amongst males is higher (9.5/100 PYAR) than for females (4.4/100 PY AR) but by the end of follow-up there is virtually no difference. Adults had a higher IR than children (8.4 versus 1.8/100 PY AR) in the first 6 months, reducing to 1.8 and 0.5, respectively, by the end of follow-up. However, numbers of children involved were small. . Table 6 shows the results of the Cox proportional hazards regression analysis. The HRs under univariate analysis shows the risk of developing NFl for four variables considered separately. All four variables all have significant prognostic strength with HRs of 1.8 for male sex, 3.3 for adult age, 14 for presence of long-standing NFl at registration and 16 for MB leprosy group. However, when the four variables are entered into a multivariate analysis, the model created does not show quite the same picture. The variables of leprosy group and presence/absence of long-standing NFl at registration still have significant HRs of 8.8 (95% CI 6.2-12) and 6.1 (4.4-8.6) respectively, but the HRs for sex and leprosy group are not significant at the 5% level (limits for the 95% CI fall below 1). This shows that it is the risk factors of leprosy group and presence/absence of long-standing NFl at registration that are the key determinants of future NFl risk.
Discussion
PROPORTIONS OF PATIENTS DEVELOPING EPISODES OF NFl
The published prevalence of reversal reactions and NFl occurring at first examination and during MDT has been comprehensively reviewed. 1l , 1 2 Amongst MB patients in field-based studies, they range from 9.6% in Indonesia 1 3 to 41 % in Ethiopia, 14 placing the results of this study, 36% with acute NFl, near the top end of the range. However, there are considerable problems with comparison of results since the definition of 'reversal reaction' varies from one study to another. In addition, definitions of PB and MB classifications are not consistent. Amongst PB patients in this study, the proportion of 4.4% developing NFl either before or after registration compares with the results from other studies, ranging from 3.7 to 14%. Amongst both MB and PB cases, the majority of new NFl occurred aft er registration. Schreuder found that the majority, 82% of PB cases developing reversal reaction, did so before registration.
The majority of patients in the study developing NFl events did so in the first year (75%), and this is a common finding. II -B , IS Although the proportion of patients experiencing their first NFl event diminishes with time, amongst MB patients there is a moderate number who have their first episode after 18 months of MDT (10.1 % of all those who develop NFl, 3.6% of all MB patients). This highlights the importance of continuing vigilance after registration for at least 2 years, especially in the case of MB patients, and probably thereafter as well since it is known that NFl and reactions continue after 2 years. 11 These results are important, since treatment regimens are becoming shorter. The WHO is now recommending 12-month treatment for MB cases, and a 6-month course for PB cases with two to five skin patches. 1 6 Active surveillance may cease after treatment has been completed for both MB and PB cases in many LCPs, making it very important both to educate patients adequately about the symptoms of NFl and reaction, and to make it easy for such patients to refer themselves back to leprosy clinics. Fortunately, there is evidence that such an approach is effective for most patients who develop late reactions. 17
INCIDENCE RATES OF NFl AND REACTIONS, AND HAZARD RATIOS
A broad pattern emerges, indicating that the IRs of NFl, type 1 skin reaction and silent NFl are considerably higher amongst MB patients compared with PB patients, and amongst patients with long-standing NFl present at registration compared with those without it. In addition, incidences are higher amongst males than females and adults than children, although the differences are much less marked. However, there are problems with nerve function testing in children, so results must be interpreted with caution. Other studies show a similar picture amongst MB and PB patients, although the rates given are lower than those in the present study: 11100 PYAR amongst PB cases and 12/100 amongst MB cases in Nepal; 1 2 11100 and 6/ 100 respectively in an earlier, retrospective study at DBLM in Bangladesh; 1 8 and 1.9/100 PYAR during the first 6 months of PBIMDT, 141100 PYAR during 24 months of MBI MDT in Thailand. 1I These compare with rates of 1.3 and 2411 00 PY AR respectively in the present study. Again, comparisons must be made with caution, since there is a lack of agreement between authors about definitions of reactive events.
In Nepal, van Brakel found that the risk of developing NFl was 5 times greater amongst patients with 'extensive disease' (three or more body areas involved, roughly equivalent to our MB classification) than amongst patients with more limited disease; 19 this is similar to the finding of a significant HR of 8.8 in the multivariate analysis. Van Brakel highlighted the importance of the presence of extensive disease, identified by a body area count, as an indicator of the risk of reversal reaction. The present study strongly supports this evidence. However, Roche and others only found an odds ratio of 1.3 for 'neural type 1 reaction' in a retrospective study, also carried out in Nepa1. 2 o In this study, the IR amongst patients with long-term NFl present at registration is even higher than that amongst MB cases (27 versus 241100 PY AR amongst MB patients), and this has emerged as another strong risk factor for the development of NFl after registration, with a HR of 14 in the univariate and 6. 1 in the multivariate analysis. Roche found that a disability index of >0 carried an odds ratio of 2.6 for 'neural type 1 reaction' ; 2 0 however, Schreuder found that a WHO disability grade of 1 or 2 was not a significant risk factor for the development of a reversal reaction during treatment, although it was a significant risk-factor for reversal reaction present at the time of registration. 11 In Ethiopia, de Rijk and others found that PB patients with WHO disability grade 1 or 2 had significantly more NFl/reactive events than those without disability, but that was not true for MB patients. 14 It is true that MB leprosy group and the presence of long-standing NFl at registration overlap to a certain extent, NFl being more common amongst MB patients. However, there are a large number of MB patients who do not have impairment at registration.
Whilst the IR was higher amongst males compared with females, and adults compared with children, this was much less marked than with the other two risk variables. Neither van Brakel nor Roche found that male sex had a statistically significant predictive value for the development of type 1 reaction. 1 2 , 2 0 The multivariate analysis carried out here shows that the apparently significant predictive strength of age and sex are not significant at the 5% level in a multivariate model which includes leprosy group and presence/absence of long-standing Nfl at registration as co-variables. This indicates that it is leprosy group and the presence/absence of NFl at registration which are the key risk factors for predicting future NFl amongst leprosy patients and that age and sex can safely be ignored as risk factors.
It is interesting that whilst the IR of NFl amongst patients with long-standing NFl present at registration is 15 times higher than amongst those without, it is only twice as high for type 1 reactions. It appears that the two types of reaction, one with a skin component and the other without, are independent of each other, supporting immunological evidence of antigenic heterogeneity between patients with skin and nerve disease predominating ? 1 A study in Hyderabad, India found that a first symptom-to-reaction time amongst patients with neurological symptoms was twice as long as that amongst patients with skin symptoms. 22 Roche found that only 7% of cutaneous type 1 reactions occurred after 6 months of treatment, but 32% of neural type 1 reactions, 23 again supporting the view that skin and nerve reactions are relatively independent of one another.
Most patients (86%) developing an NFl event after registration experienced it 'silently', i.e. without a skin reaction or the development of nerve pain. This concurs with findings from other studies, 1 2 , 14 and highlights the need for regular nerve function testing to be available for patients at clinic visits, and for patients to be aware that developing numbness in hands or feet must not be ignored. The IR of silent NFl, 3.2/100 PYAR, is close to that found in Nepal (4. 1). 5 It is perhaps more informative to compare the IRs of type 1 reaction with this silent NFl group, since the cases included in these two are mutually exclusive (,All NFl' patients include 24 who were included in the 'type 1 reaction' group). The differences noted in the paragraph above are even more marked when this comparison is made.
The IR for SNFI is over double that for MNFI (2.7 versus 1.3/100 PYAR, respectively). This study used the ballpoint test. Rates for SNFI could be expected to be relatively higher if more sensitive tests were performed using graded monofilaments. Van Brakel found rates considerably higher than ours (SNFI, 13/100 PY AR; MNFI, 7.5/100 PY AR 19 ), but his study had a higher proportion of MB patients. In the present study, rates of SNFI and MNFI were much higher amongst the MB group (19 and 9.37/100 PYAR, respectively). It is sensory impairment which is potentially more damaging for patients, since loss of protective sensation can lead to ulceration and loss of digits unless the patient exercises great care.
The graphs showing cumulative incidence are the graphical complements to the IRs and RRs. They show clear differences in incidence between the risk factors in each category, much more marked for leprosy group and presence/absence of long-term NFl than for sex and age, although all of the differences shown are statistically significant (P < 0.001). These curves bring into even sharper focus the importance of considering leprosy group and presence/absence of long-term Nfl at registration time in predicting the probability of developing NFl after registration.
The IRs presented for successive 6-month periods during follow-up (cf. Table 5) show some interesting trends. These statistics show as rates per 100 PY AR what was expressed as a simple proportion in Figure 1 . During the first 6 months the IRs for all risk variables are at their highest, and it is during this period that patients and leprosy control staff need to be at their most vigilant, especially for ME patients and patients with a history of NFl present at registration.
It should be borne in mind that these findings are being presented at a relatively early stage and that there is one more year of follow-up for PB patients and three more for MB patients to run in the study. There is an incidence of 'late' reversal reactions or NFl occurring in the third and fourth years after RFT, although amongst PB patients this is almost zero. In Malawi only 21 17 reversal reactions occurred after the first year, since RFT amongst 498 PB patients (0.4%), 2 4 and there were none in Thailand. ll At Karigiri, India, only 11 patients 0.1%) of 980 MB leprosy patients developed a reaction during 10 years of post-MDT surveillance, and most of these did so within the first 3 years. 2 5 In Thailand, 21218 ME patients 0%) had a reversal reaction, and 11218 (0.5%) an episode of silent neuropathy in the third year after registration. Given these very low incidences, it is safe to assume that the figures presented in this study for 2 years of follow-up are close to the total number that will occur.
Eight patients developed an ENL reaction during treatment, out of 84 BL and 51 LL patients in the cohort. Only one patient at registration had an ENL reaction present, bringing the total to nine (6.7% of lepromatous patients). This compares with 12% found in Thailand, ll 17/175 (9.7%) in Nepal, 1 2 11% in Zaire 2 6 and only 2/149 (1.3%) in Ethiopia. 14 In conclusion, an analysis of NFl events occurring in a large prospective cohort of newly registered leprosy patients has been carried out. Whilst most NFl events occurred either before registration or during the first year after the start of MDT, amongst MB patients almost a third occurred in the second year of MDT. The IRs of NFl amongst MB patients and those with long-standing NFl present at registration are particularly high, and whilst the IR reduced over time, it was maintained at a moderately high level amongst these latter two groups of patients even at the end of follow-up. The presence of long-standing NFl at registration and MB group have emerged as important predictors for the development of NFl after registration in a regression model which included age and sex as co-variables. The subject of predicting NFl and the development of a prediction rule is an important area requiring further investigation, both for understanding the pathogenesis of nerve damage in leprosy and implementing leprosy control programmes.
